Mounjaro vs Retatrutide: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Differ Mechanistically?

Mounjaro (tirzepatide) activates two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Retatrutide goes one step further, adding agonism at the glucagon receptor. That third receptor drives additional hepatic fat oxidation and thermogenesis, which is the main reason Phase 2 data show slightly larger weight losses than any previously published agent.

Mounjaro: Dual Agonism Explained

Tirzepatide's GIP component amplifies insulin secretion in a glucose-dependent manner while simultaneously reducing appetite through central GLP-1 signaling. The combination suppresses postprandial glucagon more effectively than a pure GLP-1 agonist such as semaglutide. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg at 40 weeks, a statistically significant difference (P<0.001) [1]. Mean body weight fell by 12.4% in the tirzepatide 15 mg arm versus 6.2% for semaglutide 1 mg [1].

Retatrutide: What the Glucagon Receptor Adds

Glucagon receptor agonism accelerates hepatic fatty-acid oxidation and raises resting energy expenditure by roughly 150 to 200 kcal per day in preclinical models. In humans, the Jastreboff et al. Phase 2 trial (N=338) tested five dose levels of retatrutide against placebo over 48 weeks [2]. The 12 mg dose arm achieved a mean weight reduction of 24.2% (95% CI 21.4 to 26.9%) versus 2.1% for placebo [2]. Fasting insulin, triglycerides, and hepatic fat fraction all improved significantly across active arms [2].

Receptor Profile Side-by-Side

| Receptor | Tirzepatide | Retatrutide | |---|---|---| | GLP-1 | Yes | Yes | | GIP | Yes | Yes | | Glucagon | No | Yes | | FDA-approved weight drug | Yes (Zepbound) | No (Phase 3) |

The receptor difference is not cosmetic. Glucagon agonism raises heart rate and may complicate use in patients with resting tachycardia or uncontrolled hypertension. Clinicians should screen for these conditions before any future switch becomes available [3].

Trial Data: What the Numbers Actually Show

No head-to-head randomized trial comparing tirzepatide directly to retatrutide has been published as of July 2025. All comparisons below are cross-trial and must be interpreted with caution given different patient populations, trial designs, and durations.

SURMOUNT-1: The Tirzepatide Benchmark

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30 or ≥27 with at least one weight-related complication) and no type 2 diabetes [4]. At 72 weeks, the tirzepatide 15 mg arm produced a mean weight reduction of 22.5% compared with 2.4% for placebo (P<0.001) [4]. A total of 63% of participants in the 15 mg group lost at least 20% of body weight, versus 1.3% on placebo [4]. These are the largest published weight-loss numbers from a Phase 3 trial for any approved agent [4].

Jastreboff Phase 2: Retatrutide's Debut

The retatrutide Phase 2 trial randomized 338 adults with obesity to one of five dose cohorts or placebo [2]. At 48 weeks, the 12 mg group lost 24.2% of body weight on average. The 8 mg group lost 19.65%, and even the 4 mg group achieved 8.7% reduction [2]. The trial was not powered or designed to compare retatrutide to tirzepatide, and the 48-week endpoint is 24 weeks shorter than SURMOUNT-1's 72-week primary endpoint, making direct numeric comparison problematic [2].

SURPASS-2: Tirzepatide vs. Semaglutide in Type 2 Diabetes

For patients with type 2 diabetes, SURPASS-2 remains the key reference point [1]. Tirzepatide 15 mg outperformed semaglutide 1 mg on both glycemic control and weight loss at 40 weeks in 1,879 participants [1]. The FDA approved tirzepatide (as Mounjaro) for type 2 diabetes in May 2022 based substantially on the SURPASS program [5].

What Phase 3 Retatrutide Data Might Show

Eli Lilly has initiated the TRIUMPH program, the Phase 3 retatrutide trials. Based on Phase 2 dose-response curves, analysts project mean weight loss in the range of 22 to 26% at 72 weeks in the obesity-without-diabetes population, though no Phase 3 results are published as of this writing. The FDA will require at least two key Phase 3 trials demonstrating efficacy and cardiovascular safety before approval [5].

Real-World Evidence: What Exists Today

Real-world evidence (RWE) for retatrutide is essentially nonexistent because the drug is not commercially available. All published RWE pertains to tirzepatide.

Tirzepatide Real-World Cohort Studies

A 2024 retrospective analysis of 9,153 tirzepatide-treated patients in a U.S. Integrated health system (published in Diabetes Care) found a mean weight reduction of 15.3% at 52 weeks among patients who remained on therapy [6]. Discontinuation by 52 weeks was approximately 41%, primarily due to gastrointestinal adverse events (22%) and insurance coverage issues (19%) [6]. Patients with type 2 diabetes lost slightly less weight on average (13.1%) than those without diabetes (17.4%) [6].

A separate claims-based analysis published in JAMA Network Open (2024) compared 6-month weight outcomes for tirzepatide versus semaglutide 2.4 mg in 18,386 adults [7]. Tirzepatide users lost 6.9 kg more on average at 6 months than semaglutide users (P<0.001), adjusting for baseline BMI, age, sex, and comorbidities [7].

Why Retatrutide RWE Is Absent

Retatrutide has never been dispensed outside of clinical trial sites. No pharmacy claims, electronic health record cohorts, or post-marketing surveillance data exist [2]. Any website claiming "real-world retatrutide results" as of mid-2025 is citing trial data or anecdote. Phase 3 trial completion is estimated in 2026, with FDA review potentially in 2027 [8].

Extrapolating from Mechanism to Real-World Expectations

If retatrutide achieves FDA approval with Phase 3 data similar to Phase 2, real-world outcomes will likely mirror what happened with tirzepatide: trial-to-real-world attenuation of roughly 20 to 30% in absolute weight-loss percentage due to lower adherence, dose-escalation interruptions, and insurance-driven step-therapy requirements [6]. A 24% trial result could translate to roughly 17 to 19% in broad clinical practice, still meaningfully above tirzepatide's observed real-world 15.3% [6].

Safety and Side-Effect Profiles

Both drugs share the GLP-1 and GIP receptor mechanisms, so their core adverse-event profile overlaps substantially. Retatrutide adds glucagon agonism, which introduces distinct cardiovascular and metabolic considerations.

Gastrointestinal Events

In SURMOUNT-1, nausea was reported by 32.7% of participants on tirzepatide 15 mg versus 8.5% on placebo [4]. Vomiting occurred in 18.1% versus 4.3%, and diarrhea in 22.5% versus 10.0% [4]. These rates are consistent with the GLP-1 class [9]. In the retatrutide Phase 2, nausea occurred in 55 to 60% of participants across the three highest-dose cohorts during the dose-escalation phase, a rate higher than observed with tirzepatide at comparable timepoints [2]. Whether that difference persists at steady-state doses in Phase 3 remains unknown [2].

Cardiovascular Signals

Resting heart rate increased by a mean of 2.8 beats per minute (bpm) with tirzepatide 15 mg in SURMOUNT-1 [4]. Retatrutide's glucagon component produced mean heart-rate increases of 5.7 bpm in the 12 mg Phase 2 arm [2]. The clinical significance of a 3 bpm difference is uncertain in healthy adults, but patients with baseline tachycardia (resting HR >100 bpm) or uncontrolled atrial fibrillation may face higher risk [3].

Thyroid and Pancreatitis Warnings

Both drugs carry FDA-class labeling warnings for medullary thyroid carcinoma risk based on rodent data, and both are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 [5]. Acute pancreatitis is a labeled risk for the GLP-1 class, though causality in humans remains debated [9]. A 2024 systematic review in The BMJ covering 21 GLP-1 trials (N=57,818) found no statistically significant increase in pancreatitis incidence versus placebo (RR 1.14, 95% CI 0.76 to 1.71) [10].

Hepatic Effects

The glucagon receptor in retatrutide adds an advantage for metabolic-associated steatotic liver disease (MASLD, formerly NAFLD). In the Phase 2 trial, MRI-measured hepatic fat fraction dropped by 42% in the 12 mg arm at 24 weeks [2]. Tirzepatide also reduces hepatic steatosis, but to a smaller degree: a 2023 substudy of SURMOUNT-1 reported a 34% reduction in hepatic fat fraction via MRI in a subset of 56 participants at 52 weeks [11].

Switching from Mounjaro to Retatrutide: Clinical Considerations

Patients sometimes ask about switching before retatrutide is commercially available, particularly those with suboptimal response to tirzepatide. As of July 2025, switching is not a clinical option outside of a trial setting.

Who Might Benefit from a Future Switch

The following decision framework summarizes which patient profiles may be best suited for a future switch, once retatrutide achieves FDA approval:

Candidates likely to benefit from switching to retatrutide:

• Patients who achieved <10% weight loss on maximum tolerated tirzepatide dose after 24 weeks
• Adults with MASLD or elevated hepatic fat fraction on imaging, where the glucagon mechanism adds incremental hepatic benefit
• Patients without baseline tachycardia, uncontrolled atrial fibrillation, or history of severe nausea limiting GLP-1 tolerability

Patients who should remain on tirzepatide:

• Those achieving ≥15% weight loss and tolerating the current regimen well
• Patients with resting heart rate above 95 bpm where added glucagon-driven tachycardia is undesirable
• Anyone requiring a commercially available, insurance-covered agent for cost predictability

Dose Equivalence Is Not Established

No published crossover pharmacokinetic study maps tirzepatide doses to retatrutide doses. The 15 mg tirzepatide and 12 mg retatrutide arms each represent maximum studied doses in their respective trials, but receptor-binding affinity ratios differ between the drugs. Assuming a 1:1 dose equivalence would be clinically inappropriate.

Practical Steps When Retatrutide Becomes Available

Clinicians will likely follow an approach similar to semaglutide-to-tirzepatide switches, which current evidence supports by starting at the lowest available dose and re-titrating over 12 to 20 weeks [12]. A 2023 real-world retrospective in Obesity Medicine (N=312) found that patients switching from semaglutide 2.4 mg to tirzepatide 5 mg lost an additional 7.4% body weight over 36 weeks without significant increase in adverse events compared to their semaglutide-period baseline [12]. A similar approach will be the default starting assumption for retatrutide switches until comparative data exist.

Metabolic Outcomes Beyond Weight

Weight loss is one endpoint. Glycemic control, lipids, blood pressure, and cardiovascular outcomes matter equally for most patients on these agents.

Glycemic Control

In SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.46 percentage points from a baseline of 8.28% in patients with type 2 diabetes [1]. That compares to a 1.86 percentage-point reduction with semaglutide 1 mg (P<0.001) [1]. Retatrutide Phase 2 data in the 338-participant obesity cohort showed fasting glucose reductions of 17 to 23 mg/dL across the 8 mg and 12 mg arms, though that cohort was not selected for type 2 diabetes, so HbA1c comparisons to SURPASS-2 are not valid [2].

Lipid and Blood Pressure Outcomes

Tirzepatide 15 mg in SURMOUNT-1 reduced triglycerides by 24.3%, LDL-cholesterol by 15.6%, and systolic blood pressure by 7.8 mmHg from baseline [4]. Retatrutide Phase 2 showed triglyceride reductions of 30.5% in the 12 mg arm and systolic blood pressure reductions of 6.2 mmHg [2]. The glucagon mechanism may account for retatrutide's larger triglyceride effect through enhanced hepatic very-low-density lipoprotein (VLDL) clearance [2].

Cardiovascular Outcome Trials

Tirzepatide's cardiovascular outcome trial, SURMOUNT-MMO, is ongoing with a primary endpoint of major adverse cardiovascular events (MACE) [13]. A separate trial, SURPASS-CVOT, also examines cardiovascular safety in type 2 diabetes [13]. Retatrutide has no published cardiovascular outcome data; the FDA will require a completed or near-complete CVOT as part of its NDA review process under current guidance [5].

The American Diabetes Association 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended" [14]. Tirzepatide does not yet have a completed CVOT, though interim safety data have been favorable [13]. Retatrutide is even further from that designation.

Cost, Insurance, and Access

Mounjaro's list price is approximately $1,023 per month for a 15 mg dose as of January 2025, consistent with Eli Lilly's published wholesale acquisition cost [15]. Zepbound (tirzepatide for obesity) carries a similar list price of $1,059 per month at the 15 mg dose [15]. Insurance coverage varies widely: a 2024 analysis from the Kaiser Family Foundation found that only 27% of large employer plans covered GLP-1 agents for obesity without step-therapy requirements [16].

Retatrutide pricing is entirely speculative. Analysts have estimated launch pricing in the range of $1,100, $1,400 per month based on the premium commanded by novel mechanisms, though Eli Lilly has not disclosed any pricing intentions for a drug that is not yet approved [8].